Publication:

Antihyperlipidemic potential of methanolic extract of whole plant Chlorophytum comosum (Thunb.) Jacques in poloxamer 407 induced hyperlipidemia in Wistar Albino rats

Background Hyperlipidaemia is a major risk factor for cardiovascular diseases, and natural remedies are being explored for safer therapeutic options. Chlorophytum comosum (Thunb.) Jacques has potential medicinal properties, but its antihyperlipidemic activity has not been thoroughly investigated. The objective was to evaluate the acute oral toxicity and antihyperlipidemic potential of the methanolic extract of Chlorophytum comosum (MECC) in Wistar Albino rats.

Methods Acute oral toxicity was assessed following OECD 2001 guidelines at doses of 300 mg/kg and 2000 mg/kg. Hyperlipidaemia was induced using Poloxamer 407 (1 g/kg, i.p.). Animals were treated with MECC at low and high doses (200 and 400 mg/kg) for 21 days, while atorvastatin (10 mg/kg) was used as the standard. Body weight, lipid profile parameters (total cholesterol, triglycerides, LDL, VLDL, HDL), and liver histopathology were evaluated.

Results MECC showed no mortality or significant adverse effects, indicating its safety. Treatment with MECC resulted in dose-dependent improvements in body weight and lipid profile parameters, comparable to those observed with atorvastatin. Histopathological analysis revealed that high-dose MECC maintained near-normal hepatic architecture, indicating hepatoprotective effects.

Conclusion MECC is non-toxic and exhibits significant antihyperlipidemic activity, suggesting its potential as a therapeutic agent for managing hyperlipidaemia.